KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Research & Development (2016 - 2026)

Pfizer has reported Research & Development over the past 18 years, most recently at $2.5 billion for Q1 2026.

  • Quarterly Research & Development rose 13.03% to $2.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.7 billion through Mar 2026, up 7.35% year-over-year, with the annual reading at $10.4 billion for FY2025, 3.56% down from the prior year.
  • Research & Development was $2.5 billion for Q1 2026 at Pfizer, down from $3.2 billion in the prior quarter.
  • Over five years, Research & Development peaked at $3.2 billion in Q4 2025 and troughed at $2.2 billion in Q1 2025.
  • The 5-year median for Research & Development is $2.6 billion (2024), against an average of $2.6 billion.
  • Year-over-year, Research & Development rose 25.73% in 2022 and then decreased 11.63% in 2025.
  • A 5-year view of Research & Development shows it stood at $2.7 billion in 2022, then grew by 4.41% to $2.8 billion in 2023, then fell by 7.71% to $2.6 billion in 2024, then increased by 23.4% to $3.2 billion in 2025, then decreased by 22.33% to $2.5 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Research & Development are $2.5 billion (Q1 2026), $3.2 billion (Q4 2025), and $2.5 billion (Q3 2025).